

Jaume Alijotas-Reig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6803607/publications.pdf>

Version: 2024-02-01

111
papers

4,485
citations

116194

36
h-index

134545

62
g-index

133
all docs

133
docs citations

133
times ranked

5380
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study. <i>Rheumatology</i> , 2022, 61, 1053-1061.	0.9	16
2	Treatment of Graves' ophthalmopathy. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 93-93.	0.1	0
3	Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 675.	1.0	33
4	Clinical and therapeutic value of the adjusted Global Antiphospholipid Syndrome Score in primary obstetric antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 354-362.	0.8	5
5	Comparing pregnancy outcomes in patients with criteria and non-criteria autoimmune disease: A systematic review. <i>Lupus</i> , 2022, 31, 5-18.	0.8	4
6	Antiphospholipid antibodies in women with recurrent embryo implantation failure: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 103101.	2.5	9
7	Inflammatory immune-mediated adverse reactions induced by COVID-19 vaccines in previously injected patients with soft tissue fillers: A case series of 20 patients. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 3181-3187.	0.8	11
8	Evaluating the Effect of Pravastatin in Early-Onset Fetal Growth Restriction: A Nonrandomized and Historically Controlled Pilot Study. <i>American Journal of Perinatology</i> , 2021, 38, 1472-1479.	0.6	15
9	Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy. <i>American Journal of Reproductive Immunology</i> , 2021, 85, e13384.	1.2	45
10	Increased risk of late-onset, immune-mediated, adverse reactions related to dermal fillers in patients bearing HLA-B*08 and DRB1*03 haplotypes. <i>Dermatologic Therapy</i> , 2021, 34, e14644.	0.8	26
11	Does incomplete obstetric antiphospholipid syndrome really exist?. <i>Medicina Clínica</i> , 2021, 156, 515-519.	0.3	4
12	Bleeding and antithrombotic therapy during pregnancy in women with poor aPL-related obstetric outcomes. <i>European Journal of Anaesthesiology</i> , 2021, 38, 916-922.	0.7	8
13	Immunological and physiopathological approach of COVID-19 in pregnancy. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 39-57.	0.8	25
14	Does incomplete obstetric antiphospholipid syndrome really exist?. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 515-519.	0.1	0
15	Tratamiento de la oftalmopatía de Graves. <i>Medicina Clínica</i> , 2021, 158, 93-93.	0.3	0
16	Chronic Villitis of unknown etiology (VUE): Obstetrical features, outcome and treatment. <i>Journal of Reproductive Immunology</i> , 2021, 148, 103438.	0.8	14
17	Proteomics and enriched biological processes in Antiphospholipid syndrome: A systematic review. <i>Autoimmunity Reviews</i> , 2021, 20, 102982.	2.5	4
18	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	0.9	53

#	ARTICLE	IF	CITATIONS
19	Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. <i>Rheumatology International</i> , 2020, 40, 777-783.	1.5	8
20	Angiogenic Factors and Long-Term Cardiovascular Risk in Women That Developed Preeclampsia During Pregnancy. <i>Hypertension</i> , 2020, 76, 1808-1816.	1.3	23
21	Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial. <i>Fetal Diagnosis and Therapy</i> , 2020, 47, 824-833.	0.6	12
22	Obstetrical outcome and treatments in seronegative primary APS: data from European retrospective study. <i>RMD Open</i> , 2020, 6, e001340.	1.8	23
23	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. <i>Autoimmunity Reviews</i> , 2020, 19, 102569.	2.5	173
24	Covid-19 and autoimmunity. <i>Autoimmunity Reviews</i> , 2020, 19, 102597.	2.5	418
25	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. <i>Autoimmunity Reviews</i> , 2020, 19, 102525.	2.5	22
26	Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. <i>Clinical Immunology</i> , 2019, 203, 1-8.	1.4	84
27	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019, 18, 406-414.	2.5	106
28	Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 314-318.	1.6	24
29	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018, 47, 639-646.	1.8	62
30	Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 40-55.	0.2	55
31	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. <i>Medicina Clínica</i> , 2018, 151, 215-222.	0.3	22
32	Maternal microbiota and the great obstetrical syndromes: When the enemy becomes an ally. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 141-143.	0.1	0
33	La microbiota materna y los grandes síndromes obstétricos: cuando el enemigo se convierte en aliado. <i>Medicina Clínica</i> , 2018, 150, 141-143.	0.3	0
34	Autoimmune/inflammatory syndrome induced by adjuvants "ASIA" related to biomaterials: analysis of 45 cases and comprehensive review of the literature. <i>Immunologic Research</i> , 2018, 66, 120-140.	1.3	52
35	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	2.5	62
36	Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 215-222.	0.1	2

#	ARTICLE	IF	CITATIONS
37	Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?. <i>Autoimmunity Reviews</i> , 2018, 17, 739-745.	2.5	26
38	Embarazo y enfermedades autoinmunitarias. <i>Medicina Clínica</i> , 2017, 148, 161-163.	0.3	4
39	Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 40-53.	2.9	165
40	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 730-734.	2.5	63
41	Pregnancy and autoimmune diseases. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 161-163.	0.1	0
42	Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain. <i>Thrombosis Research</i> , 2017, 156, 195-197.	0.8	0
43	TNF α -senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion. <i>Aging</i> , 2017, 9, 2411-2435.	1.4	95
44	Do knowledge of uterine artery resistance in the second trimester and targeted surveillance improve maternal and perinatal outcome? UTOPIA study: a randomized controlled trial. <i>Ultrasound in Obstetrics and Gynecology</i> , 2016, 47, 680-689.	0.9	38
45	Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 8-28.	1.2	119
46	Angiogenic Gene Expression in Down Syndrome Fetal Hearts. <i>Fetal Diagnosis and Therapy</i> , 2016, 40, 21-27.	0.6	12
47	Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 164-171.	1.2	14
48	Síndrome antifosfolípídico obstétrico. <i>Revista Clínica Española</i> , 2016, 216, 135-145.	0.2	20
49	Regulatory T cells, maternal "foetal immune tolerance and recurrent miscarriage: New therapeutic challenging opportunities. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 265-268.	0.1	1
50	THU0396...The Efficacy of Hydroxychloroquine for Obstetrical Outcome in Anti-Phospholipid Syndrome: Data from a European Multicenter Retrospective Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 340.1-340.	0.5	0
51	Recurrent miscarriage: causes, evaluation and management. <i>Postgraduate Medical Journal</i> , 2015, 91, 151-162.	0.9	186
52	The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2015, 14, 498-502.	2.5	152
53	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. <i>Autoimmunity Reviews</i> , 2015, 14, 387-395.	2.5	121
54	Human adjuvant-related syndrome or autoimmune/inflammatory syndrome induced by adjuvants. Where have we come from? Where are we going? A proposal for new diagnostic criteria. <i>Lupus</i> , 2015, 24, 1012-1018.	0.8	33

#	ARTICLE	IF	CITATIONS
55	Regulatory T cells, maternal-foetal immune tolerance and recurrent miscarriage: New therapeutic challenging opportunities. <i>Medicina Clínica</i> , 2015, 144, 265-268.	0.3	16
56	Obstetrical APS: Is there a place for hydroxychloroquine to improve the pregnancy outcome?. <i>Autoimmunity Reviews</i> , 2015, 14, 23-29.	2.5	62
57	Erratum to Ruffatti et al. "Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicenter retrospective study" (<i>Thromb Haemost</i> 2014; 112: 727-725). <i>Thrombosis and Haemostasis</i> , 2014, 112, 1327-1327.	1.8	1
58	Maternal and foetal angiogenic imbalance in congenital heart defects. <i>European Heart Journal</i> , 2014, 35, 701-707.	1.0	100
59	Potentiating maternal immune tolerance in pregnancy: A new challenging role for regulatory T cells. <i>Placenta</i> , 2014, 35, 241-248.	0.7	146
60	Fastest molecular photochromic switches based on nanosecond isomerizing benzothiazolium azophenolic salts. <i>Journal of Materials Chemistry C</i> , 2014, 2, 474-480.	2.7	40
61	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. <i>Thrombosis and Haemostasis</i> , 2014, 112, 727-735.	1.8	102
62	Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 241-258.	1.6	116
63	Late-Onset Inflammatory Adverse Reactions Related to Soft Tissue Filler Injections. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 97-108.	2.9	102
64	Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. <i>Lupus</i> , 2013, 22, 6-17.	0.8	68
65	Cell-derived microparticles and vascular pregnancy complications: a systematic and comprehensive review. <i>Fertility and Sterility</i> , 2013, 99, 441-449.	0.5	38
66	Expectant management in pregnant women with early and severe preeclampsia and concomitant risk factors. <i>Pregnancy Hypertension</i> , 2013, 3, 235-241.	0.6	2
67	Smoking during Pregnancy: Changes in Mid-Gestation Angiogenic Factors in Women at Risk of Developing Preeclampsia According to Uterine Artery Doppler Findings. <i>Hypertension in Pregnancy</i> , 2013, 32, 50-59.	0.5	25
68	Pseudocystic Encapsulation: A Late Noninflammatory Complication of Hyaluronic Acid Filler Injections. <i>Dermatologic Surgery</i> , 2013, 39, 1726-1728.	0.4	13
69	Current Concepts and New Trends in the Diagnosis and Management of Recurrent Miscarriage. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 445-466.	0.2	116
70	Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets. <i>Lupus</i> , 2012, 21, 257-263.	0.8	18
71	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A preliminary first year report. <i>Lupus</i> , 2012, 21, 766-768.	0.8	61
72	First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology. <i>Human Reproduction</i> , 2012, 27, 358-365.	0.4	21

#	ARTICLE	IF	CITATIONS
73	Pregnancy in women with portal vein thrombosis: Results of a multicentric European study on maternal and fetal management and outcome. <i>Journal of Hepatology</i> , 2012, 57, 1214-1219.	1.8	46
74	Autoimmune/inflammatory syndrome (ASIA) induced by biomaterials injection other than silicone medical grade. <i>Lupus</i> , 2012, 21, 1326-1334.	0.8	30
75	Study of biomaterial-induced macrophage activation, cell-mediated immune response and molecular oxidative damage in patients with dermal bioimplants. <i>Immunobiology</i> , 2012, 217, 44-53.	0.8	30
76	Angiogenic and antiangiogenic factors before and after resolution of maternal mirror syndrome. <i>Ultrasound in Obstetrics and Gynecology</i> , 2012, 40, 367-369.	0.9	35
77	Tacrolimus in the Treatment of Chronic and Refractory Late-Onset Immune-Mediated Adverse Effects Related to Silicone Injections. <i>Dermatologic Surgery</i> , 2012, 38, 38-47.	0.4	24
78	Circulating Cell-Derived Microparticles in Severe Preeclampsia and in Fetal Growth Restriction. <i>American Journal of Reproductive Immunology</i> , 2012, 67, 140-151.	1.2	24
79	Foreign-Body Granuloma After Injection of Calcium Hydroxylapatite for Treating Urinary Incontinence. <i>Obstetrics and Gynecology</i> , 2011, 118, 1181-1182.	1.2	3
80	Circulating Cell-Derived Microparticles in Women with Pregnancy Loss. <i>American Journal of Reproductive Immunology</i> , 2011, 66, 199-208.	1.2	28
81	Adverse reactions caused by different filler injections in the same region. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 736-737.	1.3	4
82	Is Obstetric Antiphospholipid Syndrome a Primary Nonthrombotic, Proinflammatory, Complement-Mediated Disorder Related to Antiphospholipid Antibodies?. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 39-45.	0.2	43
83	Inherited Antithrombin Deficiency and Pregnancy: Maternal and Fetal Outcomes. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 366-367.	0.2	0
84	Bioengineered hyaluronic acid elicited a nonantigenic T cell activation: Implications from cosmetic medicine and surgery to nanomedicine. <i>Journal of Biomedical Materials Research - Part A</i> , 2010, 95A, 180-190.	2.1	20
85	Letter: Vasculitis Related to Non-Animal Hyaluronic Acid Skin Filler Injection. <i>Dermatologic Surgery</i> , 2010, 36, 272-273.	0.4	2
86	Polyalkylimide Implant: Critical Evaluation of a Clinical Study—Reply. <i>Archives of Dermatology</i> , 2010, 146, 918.	1.7	1
87	Are Bacterial Growth and/or Chemotaxis Increased by Filler Injections? Implications for the Pathogenesis and Treatment of Filler-Related Granulomas. <i>Dermatology</i> , 2010, 221, 356-364.	0.9	33
88	Anti-annexin A5 antibodies in women with spontaneous pregnancy loss. <i>Medicina Clínica</i> , 2010, 134, 433-438.	0.3	17
89	Inherited antithrombin deficiency and pregnancy: Maternal and fetal outcomes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 149, 47-51.	0.5	42
90	Anti- β 2-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss. <i>Fertility and Sterility</i> , 2010, 93, 2330-2336.	0.5	30

#	ARTICLE	IF	CITATIONS
91	Late-Onset Immune-Mediated Adverse Effects after Poly-L-Lactic Acid Injection in Non-HIV Patients: Clinical Findings and Long-Term Follow-Up. <i>Dermatology</i> , 2009, 219, 303-308.	0.9	33
92	Medical-grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2009, 90B, 510-520.	1.6	29
93	Delayed Immune-Mediated Adverse Effects Related to Polyacrylamide Dermal Fillers. <i>Dermatologic Surgery</i> , 2009, 35, 360-366.	0.4	38
94	Recurrent Urticarial Vasculitis Related to Nonanimal Hyaluronic Acid Skin Filler Injection. <i>Dermatologic Surgery</i> , 2009, 35, 395-398.	0.4	14
95	Circulating microparticles, lupus anticoagulant and recurrent miscarriages. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 145, 22-26.	0.5	21
96	Immunological Puzzle Related to Recurrent Miscarriage: Overview. <i>Current Immunology Reviews</i> , 2009, 5, 175-186.	1.2	14
97	Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 150-161.	1.3	106
98	ORIGINAL ARTICLE: Are Anti-Beta ₂ -Glycoprotein I Antibodies Markers for Recurrent Pregnancy Loss in Lupus Anticoagulant/Anticardiolipin Seronegative Women?. <i>American Journal of Reproductive Immunology</i> , 2008, 60, 229-237.	1.2	15
99	Recurrent Kikuchi-Fujimoto disease during pregnancy: Report of case evolving into systemic lupus erythematosus and review of published work. <i>Journal of Obstetrics and Gynaecology Research</i> , 2008, 34, 595-598.	0.6	15
100	Recurrent Kikuchi-Fujimoto necrotizing lymphadenitis during pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 140, 144-145.	0.5	3
101	Acute Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2008, 358, 2744-2746.	13.9	6
102	Delayed Immune-Mediated Adverse Effects of Polyalkylimide Dermal Fillers. <i>Archives of Dermatology</i> , 2008, 144, 637-42.	1.7	44
103	Cervical pregnancy complicated with group B streptococcal meningitis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2007, 20, 423-425.	0.7	5
104	Aspirin Desensitization in the Treatment of Antiphospholipid Syndrome during Pregnancy in ASA-sensitive Patients. <i>American Journal of Reproductive Immunology</i> , 2006, 55, 45-50.	1.2	24
105	Letter to the Editor. <i>Lupus</i> , 2004, 13, 554-554.	0.8	1
106	Life-Threatening Bleeding, Pregnancy and Lupus Anticoagulant: Success after Steroid and Anticoagulant Therapy. <i>American Journal of Reproductive Immunology</i> , 2004, 52, 129-132.	1.2	6
107	Sarcoidosis, s'Androme de L'Åfgren y febre uveoparot'idea (caso 145-2003). <i>Medicina Cl'nica</i> , 2004, 123, 478b-478.	0.3	1
108	Antinuclear Autoantibodies, Complement Level, Hypergammaglobulinemia and Spontaneous Intrauterine Hematoma in Pregnant Women. <i>American Journal of Reproductive Immunology</i> , 2003, 50, 1-6.	1.2	13

#	ARTICLE	IF	CITATIONS
109	Anticuerpos antifosfolípido, osteonecrosis e infección por el virus de la inmunodeficiencia humana. Medicina Clínica, 2003, 120, 236-236.	0.3	1
110	Effectiveness and safety of prehospital urapidil for hypertensive emergencies. American Journal of Emergency Medicine, 2001, 19, 130-133.	0.7	34
111	Polymyositis and cyclosporin A.. Annals of the Rheumatic Diseases, 1990, 49, 66-66.	0.5	14